NEW YORK (GenomeWeb) – Leerink today initiated coverage of liquid biopsy-based diagnostics firm Trovagene with an Outperform rating. 

Analyst Dan Leonard gave the San Diego-based company's shares a $9 price target, and in a report, he noted the sizeable liquid biopsy market opportunity — which he pegged at a minimum of $10 billion long term — calling it "a market with the potential … to be the largest in molecular diagnostics." 

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

CNN reports that researchers have tied a new variant to opioid addiction risk.

Organoids derived from patients' tumors may help determine what chemotherapy treatment patients would benefit from, according to New Scientist.

An initiative from GenomeAsia 100K hopes to increase the number of South Asians in genetic research, according to NBC News.

In Science this week: genomic analysis of ancient and modern horses indicates population turnover, and more.

Sponsored by
Swift Biosciences

This webinar will discuss an optimized protocol for methyl-CpG binding domain sequencing (MBD-seq), which enables comprehensive, adequately powered, and cost-effective large-scale methylome-wide association studies (MWAS) of almost all 28 million CpG sites in the genome.

Sponsored by

This webinar will discuss how acoustic liquid handling can reduce the time and costs for labs performing carrier screening with next-generation sequencing.